|Dr. Vasant Narasimhan||Chief Exec. Officer||2.7M||N/A||1976|
|Mr. Harry Kirsch||Chief Financial Officer||2.88M||N/A||1965|
|Mr. Steven Baert||Head of HR||2.4M||N/A||1974|
|Mr. Richard Francis||Chief Exec. Officer of Sandoz||3.01M||N/A||1968|
|Dr. James E. Bradner M.D.||Pres of Novartis Institutes for Biomedical Research||3.03M||N/A||1972|
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; QIAGEN N.V.; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; and Conatus Pharmaceuticals Inc. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Novartis AG’s ISS Governance QualityScore as of December 1, 2018 is 2. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 9; Compensation: 1.